Close

Agenus (AGEN) Commencement of Phase 1/2 Clinical Trial of anti-OX400 in Patients with Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. SPY
3. SHW
4. AMZN
5. TSLA
6. NVDA
7. SPOT
8. MTTR
9. CDNS
10. ADBE


Go back to Agenus (AGEN) Commencement of Phase 1/2 Clinical Trial of anti-OX400 in Patients with Solid Tumors
AGENUS (NASDAQ: AGEN) Delayed: 6.05 +0.28 (4.85%)
Previous Close $5.77    52 Week High $7.49 
Open $5.76    52 Week Low $2.61 
Day High $6.09    P/E N/A 
Day Low $5.70    EPS $-1.10 
Volume 73,452